The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...
Pathology, New York University Grossman School of Medicine, New York, United States The final, formatted version of the article will be published soon. The assessment of measurable residual disease ...
Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.
Acute myeloid leukemia (AML) is a malignancy characterized by the clonal proliferation of myeloid hematopoietic progenitor or stem cells, primarily ...
The SAVE regimen achieved an 86% ORR in newly diagnosed AML, with high MRD-negative rates, especially in NPM1 mutations or KMT2A rearrangements. Significant myelosuppression and infectious ...
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily ...
MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...
First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...
In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback